Syntrix's dual CXCR1/CXCR2 inhibitor for combos in oral, lung cancers

INDICATION: Lung cancer; solid tumors

Mouse studies suggest combining the dual CXCR1/CXCR2 inhibitor SX-682 with anti-PD-1 mAbs or T cell therapies could help treat oral and lung cancers. In mouse models of oral carcinoma and Lewis lung carcinoma (LLC), SX-682 plus anti-PD-1 mAbs decreased tumor growth and increased survival compared with either agent alone. In a mouse models of oral carcinoma and LLC expressing ovalbumin, SX-682 plus adoptive transfer of ovalbumin-targeting T cells decreased tumor growth and increased survival. Next steps could include testing the SX-682 combination therapies in xenograft mouse models of lung cancer...